As the recognized biomarker of systemic inflammation, CRP could also be used as a good biomarker for AMI identification and long‐term outcomes, whereas AMI increases long‐term mortality and reduces long‐term survival in older Chinese patients with CAD. Here, CRP is linked to coronary artery disorder.